Epidemiology of Gallbladder Cancer in Saudi Arabia.
Middle East
Saudi Arabia
epidemiology
gallbladder neoplasms
incidence
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
07
2020
accepted:
08
09
2020
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
17
10
2020
Statut:
epublish
Résumé
Gallbladder cancer is generally rare but can be more common in some populations. The aim of this study was to present an analysis of gallbladder cancer epidemiology in Saudi Arabia. A retrospective study of gallbladder cancer cases in Saudi Arabia from 2004 to 2015 was conducted. The gallbladder cancer data were accessed through the Saudi Cancer Registry (SCR) reports for 13 administrative regions. The number of gallbladder cancer cases with percentage, the crude incidence rate (CIR) and the age-standardised incidence rate (ASIR), stratified by regions, gender, and the years of diagnoses were analysed. A total of 1678 gallbladder cancer cases, 702 in males and 976 in females, were registered between 2004 and 2015. Saudi women and men in the 75 and above age-group were found to have the highest diagnosis rate of gallbladder cancer. In males, the overall ASIR among Saudi males was 1.1 per 100,000 (95% CI, 0.9 to 1.2). The Eastern region had the highest overall ASIR at 1.5 per 100,000 males, followed by Tabuk and Riyadh at 1.4 and 1.3 higher than other regions (F(12,143)=1.930, P<0.001). The overall ASIR among Saudi females was 1.6 per 100,000 (95% CI, 1.4 to 1.7). Riyadh had the highest overall ASIR at 2.4 per 100,000 females, followed by the Eastern region, and Qassim at 1.9 and 1.5, respectively, all higher than other provinces of the country (F(12,143)=2.496, P<0.005). The ASIR and CIR were lower among males than females (ratio 0.7). Gallbladder cancer incidence is relatively low in Saudi Arabia. The rates were higher in females than males. ASIR showed variations between different provinces of Saudi Arabia. In females, the highest ASIR was in Riyadh. In males, ASIR was highest in the Eastern region of Saudi Arabia.
Sections du résumé
BACKGROUND
BACKGROUND
Gallbladder cancer is generally rare but can be more common in some populations. The aim of this study was to present an analysis of gallbladder cancer epidemiology in Saudi Arabia.
MATERIALS AND METHODS
METHODS
A retrospective study of gallbladder cancer cases in Saudi Arabia from 2004 to 2015 was conducted. The gallbladder cancer data were accessed through the Saudi Cancer Registry (SCR) reports for 13 administrative regions. The number of gallbladder cancer cases with percentage, the crude incidence rate (CIR) and the age-standardised incidence rate (ASIR), stratified by regions, gender, and the years of diagnoses were analysed.
RESULTS
RESULTS
A total of 1678 gallbladder cancer cases, 702 in males and 976 in females, were registered between 2004 and 2015. Saudi women and men in the 75 and above age-group were found to have the highest diagnosis rate of gallbladder cancer. In males, the overall ASIR among Saudi males was 1.1 per 100,000 (95% CI, 0.9 to 1.2). The Eastern region had the highest overall ASIR at 1.5 per 100,000 males, followed by Tabuk and Riyadh at 1.4 and 1.3 higher than other regions (F(12,143)=1.930, P<0.001). The overall ASIR among Saudi females was 1.6 per 100,000 (95% CI, 1.4 to 1.7). Riyadh had the highest overall ASIR at 2.4 per 100,000 females, followed by the Eastern region, and Qassim at 1.9 and 1.5, respectively, all higher than other provinces of the country (F(12,143)=2.496, P<0.005). The ASIR and CIR were lower among males than females (ratio 0.7).
CONCLUSION
CONCLUSIONS
Gallbladder cancer incidence is relatively low in Saudi Arabia. The rates were higher in females than males. ASIR showed variations between different provinces of Saudi Arabia. In females, the highest ASIR was in Riyadh. In males, ASIR was highest in the Eastern region of Saudi Arabia.
Identifiants
pubmed: 33061639
doi: 10.2147/CMAR.S268226
pii: 268226
pmc: PMC7538003
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9527-9537Informations de copyright
© 2020 Alqahtani and Alghamdi.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Medicine (Baltimore). 2018 Jul;97(28):e11396
pubmed: 29995783
Ann Med Surg (Lond). 2018 Sep 26;35:117-123
pubmed: 30294442
Arch Surg. 2009 May;144(5):441-7; discussion 447
pubmed: 19451486
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1319-26
pubmed: 26070529
HPB (Oxford). 2015 Aug;17(8):681-90
pubmed: 26172135
Scand J Gastroenterol. 2016 Oct;51(10):1239-48
pubmed: 27232657
Cancer Manag Res. 2020 Feb 13;12:1101-1111
pubmed: 32104090
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Ecancermedicalscience. 2016 Dec 21;10:704
pubmed: 28105075
Cancer Med. 2017 Apr;6(4):874-880
pubmed: 28317286
J Clin Invest. 1991 Jan;87(1):237-46
pubmed: 1845870
Cancer Metastasis Rev. 2016 Jun;35(2):263-75
pubmed: 26857926
World J Gastroenterol. 2017 Jun 14;23(22):3978-3998
pubmed: 28652652
Radiographics. 2001 Mar-Apr;21(2):295-314; questionnaire, 549-55
pubmed: 11259693
Clin Exp Hepatol. 2019 May;5(2):93-102
pubmed: 31501784
Int J Surg. 2014;12 Suppl 2:S108-S119
pubmed: 25182380
Chin Clin Oncol. 2019 Aug;8(4):33
pubmed: 31484488
Clin Epidemiol. 2014 Mar 07;6:99-109
pubmed: 24634588
Gut Liver. 2012 Apr;6(2):172-87
pubmed: 22570746
Diabetes Metab Res Rev. 2016 Jan;32(1):63-72
pubmed: 26111736
Chin Clin Oncol. 2019 Aug;8(4):31
pubmed: 31484487
J Long Term Eff Med Implants. 2005;15(3):329-38
pubmed: 16022643
Surg Clin North Am. 2014 Apr;94(2):343-60
pubmed: 24679425
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer. 2019 May 1;125(9):1489-1498
pubmed: 30645774